Literature DB >> 6914195

Human plasma kallikrein. A rapid purification method with high yield.

H Nagase, A J Barrett.   

Abstract

A simple method for isolation of kallikrein from human plasma is described. Before activation of the enzyme with acetone, the plasma was treated with 0.2 M-methylamine at pH 8.2 to inactivate alpha 2-macroglobulin and thus prevent the irreversible binding of the active enzyme to the inhibitor. The enzyme was adsorbed on soya-bean trypsin inhibitor-Sepharose 4B and eluted with 5 mM-NaOH, pH 11.3. It was further purified by immunoadsorption of contaminating proteins, and gel chromatography on Ultrogel AcA 44. About 3 mg of kallikrein was obtained from 400 ml of plasma (35% yield). The purified enzyme was shown to be homogeneous by electrophoretic and immunological criteria. The specific activities against benzyloxycarbonylphenylalanylarginine methylcoumarylamide, prolylphenylalanylarginine methylcoumarylamide and tosylarginine methyl ester were higher than any previously reported. The purified enzyme was resolved into two forms of mol.wts. 88 000 and 86 000 in sodium dodecyl sulphate/polyacrylamide-gel electrophoresis without reduction. Each consisted of three chains linked by disulphide bonds, one containing the reactive serine residue (mol.wt. 36 000 or 34 000), and two additional chains (mol.wt. 28 000 and 22 000).

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6914195      PMCID: PMC1162589          DOI: 10.1042/bj1930187

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  32 in total

1.  Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation.

Authors:  A S Weiss; J I Gallin; A P Kaplan
Journal:  J Clin Invest       Date:  1974-02       Impact factor: 14.808

2.  [The isolation of porcine and human kallikrein using affinity chromatography: specific binding to water-insoluble Kunitz soybean-inhibitor-celluloses and dissociation with competitive inhibitors (benzamidine)].

Authors:  H Fritz; G Wunderer; B Dittmann
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1972-06

3.  Defective activation of clotting, fibrinolytic, and permeability-enhancing systems in human Fletcher trait plasma.

Authors:  H Saito; O D Ratnoff; V H Donaldson
Journal:  Circ Res       Date:  1974-05       Impact factor: 17.367

4.  Studies on prekallikrein of bovine plasma. I. Purification and properties.

Authors:  H Takahashi; S Nagasawa; T Suzuki
Journal:  J Biochem       Date:  1972-03       Impact factor: 3.387

5.  Trypsin-pancreatic trypsin inhibitor association. Dynamics of the interaction and role of disulfide bridges.

Authors:  J P Vincent; M Lazdunski
Journal:  Biochemistry       Date:  1972-08-01       Impact factor: 3.162

6.  Factor XII-induced fibrinolysis: studies on the separation of prekallikrein, plasminogen proactivator, and factor XI in human plasma.

Authors:  K Laake; A M Venneröd
Journal:  Thromb Res       Date:  1974-02       Impact factor: 3.944

7.  Chicken alpha2-proteinase inhibitor: a serum protein homologous with ovoinhibitor of egg white.

Authors:  A J Barrett
Journal:  Biochim Biophys Acta       Date:  1974-11-05

8.  The electrophoretically 'slow' and 'fast' forms of the alpha 2-macroglobulin molecule.

Authors:  A J Barrett; M A Brown; C A Sayers
Journal:  Biochem J       Date:  1979-08-01       Impact factor: 3.857

9.  Studies on the prekallikrein (kallikreinogen)--kallikrein enzyme system of human plasma. I. Isolation and purification of plasma kallikreins.

Authors:  R W Colman; L Mattler; S Sherry
Journal:  J Clin Invest       Date:  1969-01       Impact factor: 14.808

10.  Plasma prekallikrein: isolation, characterization, and mechanism of activation.

Authors:  K D Wuepper; C G Cochrane
Journal:  J Exp Med       Date:  1972-01       Impact factor: 14.307

View more
  21 in total

1.  The precursor of a metalloendopeptidase from human rheumatoid synovial fibroblasts. Purification and mechanisms of activation by endopeptidases and 4-aminophenylmercuric acetate.

Authors:  Y Okada; E D Harris; H Nagase
Journal:  Biochem J       Date:  1988-09-15       Impact factor: 3.857

2.  Activation of the plasma kallikrein-kinin system by Candida albicans proteinase.

Authors:  H Kaminishi; M Tanaka; T Cho; H Maeda; Y Hagihara
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.441

3.  Inactivation of C-1 inhibitor by proteases: demonstration by a monoclonal antibody of a neodeterminant on inactivated, non-complexed C-1 inhibitor.

Authors:  J H Nuijens; C C Huijbregts; G M van Mierlo; C E Hack
Journal:  Immunology       Date:  1987-07       Impact factor: 7.397

4.  Generation of the bioactive kallikrein-derived fragment, C3d-k, by HANE-plasma.

Authors:  T Seya; S Nagasawa; J P Atkinson
Journal:  Clin Exp Immunol       Date:  1985-10       Impact factor: 4.330

5.  Deficiency of kallikrein-like enzyme activities in cerebral tissue of patients with Alzheimer's disease.

Authors:  T Aoyagi; T Wada; M Nagai; F Kojima; S Harada; T Takeuchi; H Takahashi; K Hirokawa; T Tsumita
Journal:  Experientia       Date:  1990-01-15

6.  L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L.

Authors:  A J Barrett; A A Kembhavi; M A Brown; H Kirschke; C G Knight; M Tamai; K Hanada
Journal:  Biochem J       Date:  1982-01-01       Impact factor: 3.857

7.  Proteolytic inactivation of plasma C1- inhibitor in sepsis.

Authors:  J H Nuijens; A J Eerenberg-Belmer; C C Huijbregts; W O Schreuder; R J Felt-Bersma; J J Abbink; L G Thijs; C E Hack
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

8.  The activation of the alternative pathway C3 convertase by human plasma kallikrein.

Authors:  R G DiScipio
Journal:  Immunology       Date:  1982-03       Impact factor: 7.397

9.  Detection of tissue kallikrein in the bronchoalveolar lavage fluid of asthmatic subjects.

Authors:  S C Christiansen; D Proud; C G Cochrane
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

10.  Activation of latent collagenase by serum proteinases that interact with immobilized immunoglobulin G.

Authors:  P C Armour; S Levi; E E Golds; A R Poole; J S Mort; P J Roughley
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.